Univadis recently published the article, "Biosimilar Switching Not Suitable For All Patients" where they document the Spanish study presented at EULAR, held in June in London. Researchers demonstrated that patients with antibodies to biological
infliximab (Remicade) are less likely to benefit from an infliximab
biosimilar.
Be sure to check out the article to understand the key results and why this study matters in today's healthcare industry.
HORIZON Health Ventures is a healthcare cost management solutions company used by insurance
brokers, employee benefit consultants, third-party administrators,
insurance companies, and associations, to bring proven thought
leadership and strategy to the management of their clients healthcare
costs. To learn more about HHV and their services, please visit http://horizonhealthventures.com/
No comments:
Post a Comment